托泊替康治疗复发性卵巢癌的系统评价

为评价托泊替康在复发性卵巢癌化疗中的疗效、安全性以及成本效果,通过计算机检索MEDLINE(1966～2005年)等多个数据库资料及互联网相关文献,并用手工检索相关领域的杂志,用循证医学的方法收集有关托泊替康与其他药物相比较治疗复发性卵巢癌的随机对照试验文献.文献检索结果,纳入符合标准的RCT共4个(9篇文献),包括病人1032例,其方法学质量等级为A或B.通过评价:关于托泊替康在复发性卵巢癌的二线化疗中的临床应用,推荐用于耐药性、难治性的卵巢癌,选用治疗效果足够、毒性可以耐受的5天静脉滴注的标准治疗方案.

A systematic review of topotecan for treatment of recurrent ovarian carcinoma

In order to assess clinical therapeutic effect,safety and cost-effectiveness of topotecan(TPT)for recurrent epithelial ovarian carcinoma,literatures about randomized controlled trials of topotecan compared with other anti-cancer agents for treatment of recurrent epithelial ovarian carcinoma in many databases such as MEDLINE(1966~2005),EMBASE(1989~2004),CancerLit(1996~2003),CBMdisc(1978~2005),CNKI(1994~2005)CENTRAL(indexed by computer indexing system) and relevant journals(manually indexed) were indexed and reviewed in evidence-based medicine method.Four randomized controlled trials(RCTs) met the inclusion criteria,and their methodological quality was either level A or level B.Compared with single paclitaxel(TAX) or pegylated liposomal doxorubicin(PLD),single TPT was recommended to be used in second-line chemotherapy of drug-resistant and refractory recurrent ovarian carcinoma(ROC) and intravenous drip of enough therapeutic dosage and tolerable toxicity of TPT for 5 days was regarded as the standard scheme.